IN BRIEF: Arm's Haas to leave AstraZeneca board amid new SoftBank role

AstraZeneca PLC - Cambridge, England-based biopharmaceutical maker - Rene Haas will step down as ...

Alliance News 23 April, 2026 | 9:39AM
Email Form Facebook Twitter LinkedIn RSS

AstraZeneca PLC - Cambridge, England-based biopharmaceutical maker - Rene Haas will step down as a non-executive director on Thursday next week, the end of April, due to his increased executive duties. Haas is the chief executive officer of UK-based computer-chip designer Arm Holdings PLC and earlier this week was named to the additional role of CEO of SoftBank Group International. Japanese technology investor SoftBank Group Corp remains a major shareholder in Arm following its New York listing in 2023, retaining a 90% stake at the time.

In its announcement on Tuesday, SoftBank said Haas will coordinate semiconductor and artificial intelligence activities across its portfolio companies. Arm said the new role will be "limited and part-time" and "is not intended to detract from his responsibilities" at Arm. For its part, AstraZeneca on Thursday says: "Taking into account this additional workload, we have mutually agreed that Rene will not have enough time available to fully assume his AstraZeneca board member duties."

Current AstraZeneca stock price: 14,402.00 pence

12-month change: up 39%

By Tom Waite, Alliance News editor

Comments and questions to newsroom@alliancenews.com

Copyright 2026 Alliance News Ltd. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
AstraZeneca PLC 13,578.00
ARM Holdings PLC ADR 139.78
SoftBank Group Corp 5,837.00 JPY 3.86

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

© Copyright 2025 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures